Obesity and Alzheimer's disease

Hong Kong Journal of Psychiatry

Volumn 18, Issue 1, 2008, Pages 28-35

  Chang, C L ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Alzheimer disease; Dementia; Epidemiologic studies; Obesity; Risk factors

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; COCHRANE LIBRARY; DISEASE ASSOCIATION; EMBASE; EVIDENCE BASED MEDICINE; HUMAN; LIFESPAN; MEDLINE; OBESITY; PROSPECTIVE STUDY; RISK FACTOR;

EID: 41149094594     PISSN: 10262121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Möller HJ, Graeber MB. The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci 1998;248:111-22.
2. World Health Report 2003 - Shaping the future. Geneva: World Health Organization; 2003.
3. Centers of Disease Control and Prevention. Death: preliminary data for 2003. Natl Vital Stat Rep 2005;53:2.
4. Finch CE. Developmental origins of aging in brain and blood vessels: an overview. Neurobiol Aging 2005;26:281-91.
5. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA. Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-5.
6. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000;21;49-55.
7. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001;322:1447-51.
8. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002;137:149-55.
9. Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev 2002;1:61-77.
10. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999;53:1937-42.
11. Skoog I. Status of risk factors for vascular dementia. Neuroepidemiology 1998;17:2-9.
12. Skoog I. Vascular aspects in Alzheimer's disease. J Neural Transm Suppl 2000;59:37-43.
13. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am 2000;84:441-61.
14. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001;120:669-81.
15. Ceruli J, Lomaestro BM, Malone M. Update on the pharmacotherapy of obesity. Ann Pharmacother 1998;32:88-102.
16. Kolanowski J. A risk-benefit assessment of anti-obesity drugs. Drug Saf 1999;20:119-31.
17. Orlistat for obesity. Med Lett Drugs Ther 1999;41:55-6.
18. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Consultation. WHO Technical Report Series Numbr 854. Geneva: World Health Organization; 1995.
19. Ko GT, Cockram CS, Chow CC, Yeung V, Chan WB, So WY, et al. High prevalence of metabolic syndrome in Hong Kong Chinese - comparison of three diagnostic criteria. Diabetes Res Clin Pract 2005;69:160-8.
20. Dobbelsteyn CJ, Joffres MR, MacLean DR, Flowerdew G. A comparative evaluation of waist circumference, waist-to-hip ratio and body mass index as indicators of cardiovascular risk factors. The Canadian Heart Health Surveys. Int J Obes Relat Metab Disord 2001;25:652-61.
21. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6. Erratum in: Science 2002;297:2209.
22. Roher AE, Esh C, Rahman A, Kokjohn TA, Beach TG. Atherosclerosis of cerebral arteries in Alzheimer disease. Stroke 2004;35(11 Suppl 1): S2623-7.
23. Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JC 3rd. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 1995;131:162-9.
24. Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 1999;10:1699-705.
25. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998;95:6460-4.
26. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci USA 2001;98:5815-20.
27. Nalbantoglu J, Gilfix BM, Bertrand P, Robitaille Y, Gauthier S, Rosenblatt DS, et al. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. Ann Neurol 1994;36:889-95.
28. Berr C, Hauw JJ, Delaère P, Duyckaerts C, Amouyel P. Apolipoprotein E allele epsilon 4 is linked to increased deposition of the amyloid beta-peptide (A-beta) in cases with or without Alzheimer's disease. Neurosci Lett 1994;178:221-4.
29. Uusitupa MI, Karhunen L, Rissanen A, Franssila-Kallunki A, Niskanen L, Kervinen K, et al. Apolipoprotein E phenotype modifies metabolic and hemodynamic abnormalities related to central obesity in women. Am J Clin Nutr 1996;64:131-6.
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
31. Razay G, Wilcock GK. Hyperinsulinaemia and Alzheimer's disease. Age Ageing 1994;23:396-9.
32. Razay G, Vreugdenhil A, Wilcock G. Obesity, abdominal obesity and Alzheimer disease. Dementia Geriatr Cogn Disord 2006;22:173-6.
33. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hänninen T, Soininen H, et al. Association of metabolic syndrome with Alzheimer disease. Neurology 2006;67:843-7.
34. Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vascu Biol 2000;20:2255-60.
35. Kivipelto M, Helkala EL, Lasskso MP, Hänninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001;322:1447-51.
36. Yamada M, Kasagi F, Sasaki H, Masunari N, Mimiori Y, Suzuki G. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc 2003;51:410-4.
37. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005;62:1556-60.
38. Rosengren A, Skoog I, Gustafson D, Wilhelmsen L. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch Intern Med 2005;165:321-6.
39. Stewart R, Masaki K, Xue QL, Peila R, Petrovitch H, White LR, et al. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 2005;62:55-60.
40. Whitmer RA, Gunderson EP, Quesenberry CP Jr, Zhou J, Yaffe K. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res 2007;4:103-9.
41. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995;45:1161-8.
42. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003;163:1524-8.
43. Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005;65:892-7.
44. Hayden KM, Zandi PP, Lyketsos CG, Khachaturian AS, Bastian LA, Charoonruk G, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord 2006;20:93-100.
45. Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R. Measures of adiposity and dementia risk in elderly persons. Arch Neurol 2007;64:392-8.
46. Ritchie K, Lovestone S. The dementias. Lancet 2002;360:1759-66.
47. Farlow MR. Alzheimer's disease. Continuum Lifelong Learning Neurol 2007;13:39-68.
48. White H, Pieper C, Schmader K, Fillenbaum G. Weight change in Alzheimer's disease. J Am Geriatr Soc 1996;44:265-72.
49. Cronin-Stubbs D, Beckett LA, Scherr PA, Field TS, Chown MJ, Pilgrim DM, et al. Weight loss in people with Alzheimer's disease: a prospective population based analysis. BMJ 1997;314:178-9.
50. White H, Pieper C, Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc 1998;46:1223-7.
51. Barrett-Connor E, Edelstein SL, Corey-Bloom J, Wiederholt WC. Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc 1996;44:1147-52.
52. Stevens J, Cai J, Juhaeri, Thun MJ, Williamson DF, Wood JL. Consequences of the use of different measures of effect to determine the impact of age on the association between obesity and mortality. Am J Epidemiol 1999;150:399-407.
53. Visscher TL, Seidell JC, Molarius A, van der Kuip D, Hofman A, Witteman JC. A comparison of body mass index, waist-hip ratio and waist circumference as predictors of all-cause mortality among the elderly: the Rotterdam study. Int J Obes Relat Metab Disord 2001;25:1730-5.
54. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004;79:379-84.
55. Going S, Williams D, Lohman T. Aging and body composition: biological changes and methodological issues. Exerc Sport Sci Rev 1995;23:411-58.
56. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in adults - The Evidence Report. National Institutes of Health. Obes Res 1998;6(Suppl 2):S51-209.
57. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am 2000;84:441-61.
58. McGuire MT, Wing RR, Klem ML, Hill JO. Behavioral strategies of individuals who have maintained long-term weight losses. Obes Res 1999;7:334-41.
59. Methods for voluntary weight loss and control. NIH Technology Assessment Conference Panel. Consensus Development Conference, 30 March to 1 April 1992. Ann Intern Med 1993;119:764-70.
60. Assmann G, Schulte H. Results and conclusions of the Prospective Cardiovascular Munster (PROCAM) Study. In: Assmann G, editor. Lipid metabolism disorders and coronary heart disease. Munchen: MMV Medizin Verlag; 1989.
61. Assmann G, Schulte H. Modelling the Helsinki Heart Study by means of risk equations obtained from the PROCAM Study and the Framingham Heart Study. Drug 1990;40(Suppl 1):S13-8.